Novo Nordisk filed for approval of an oral, 25-mg formulation of its weight loss blockbuster “earlier this year,” according to a company spokesperson. Novo Nordisk has filed for U.S. approval of an ...

What if you could lose weight with a daily pill instead of painful weekly jabs like you would with Ozempic, the injectable form of semaglutide that controls both blood sugar and obesity? US ...

American pharmaceutical company Eli Lilly and Company this week announced results from a late-stage clinical trial for its oral diabetes medicine, orforglipron. The once-daily pill, currently ...

Rabat – OCP Green Water, a company under Morocco’s OCP Group, has secured MAD 6 billion ($620 million) in financing to expand its desalination projects. The funding was provided by the Caisse ...

EL PASO, Texas (KTSM) — Multiple New Mexico and federal law-enforcement agencies disrupted a drug trafficking organization, seized over 12,000 fentanyl pills and arrested three people, according to ...

Eli Lilly stocks displayed a major rise after the announcement of a new oral weight-loss drug that has put pressure on its rival pharmaceutical companies Eli Lilly’s stock surged 16% after the ...

A new oral weight-loss pill could offer a more convenient alternative to injectable drugs like Ozempic and Wegovy. Credit: Medicaleditswiki / Public domain A once-daily weight loss pill that mimics ...

Eli Lilly (NYSE: LLY) stock jumped over 14% on Thursday, powered by highly promising Phase 3 results for orforglipron, an oral GLP-1 receptor agonist that’s already being dubbed the “Ozempic in a pill ...

Eli Lilly’s Weight Loss Pill Turns Out To Be A Big Success In Its First Late-stage Trial On Diabetes Patients. (Image: Canva) In what comes as a massive breakthrough in the health industry, Eli Lilly, ...

From WhatsApp forwards to memes to your home medicine cabinet, Dolo-650 has become most Indians’ go-to pill. It gained massive popularity and significant consumption growth during the Covid-19 ...

Mark Huffman has been a consumer news reporter for ConsumerAffairs since 2004. He covers real estate, gas prices and the economy and has reported extensively on negative-option sales. He was ...